Navigation Links
QRxPharma Announces MOXDUO License Deal In Israel
Date:11/27/2013

SYDNEY and BEDMINSTER, N.J., Nov. 27, 2013 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today execution of a licensing agreement with ABIC Marketing Limited, the Israeli domestic subsidiary of Teva Pharmaceutical Industries Limited, for the commercialisation rights to immediate release MOXDUO in Israel.

"We are pleased to announce our strategic collaboration with Teva, the leading pharmaceutical marketing company in Israel and one of the largest in the world," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "The company's reputation, dedicated pain sales team and long-standing relationships with Israeli key opinion leaders will be an asset to the launch of MOXDUO in this market."

Under the licensing agreement, Teva will receive the exclusive rights to commercialise immediate release MOXDUO in Israel. Teva will assume responsibility for all regulatory and product launch costs as well as ongoing marketing and sales efforts. QRxPharma will receive an undisclosed up-front payment, regulatory and sales milestones, and double-digit royalties on the sales of immediate release MOXDUO in Israel. QRxPharma retains all rights to the intravenous and controlled release formulations of MOXDUO in the territory.

"Teva's interest in MOXDUO, together with that of Actavis, Paladin and Aspen, validate the need for safer opioids in the treatment of moderate to severe pain, and further endorse the commercial value of MOXDUO," added Holaday. "We are delighted to be working with such successful companies for the global commercialisation of immediate release MOXDUO."

QRxPharma will work with Teva to submit a marketing authorisation application to the Israeli health authority following approval of immediate release MOXDUO in the United States or Europe.

About QRxPharma
QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new pain management and abuse prevention products. Based on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risks and improved patient outcomes. The Company's New Drug Application for its lead product candidate immediate release MOXDUO® for the treatment of acute pain, was refiled with the US Food and Drug Administration in November 2013. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc., Aspen Group and Teva for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania), South Africa and Israel. The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology. For more information, visit www.qrxpharma.com.

Forward Looking Statements 
This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.


'/>"/>
SOURCE QRxPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QRxPharma Announces Successful Completion Of A$7.5 Million Placement
2. QRxPharma Announces Collaboration With Aesica
3. QRxPharma Granted US Patent On Hybrid Opioids
4. QRxPharma Granted Additional US Patent on MoxDuo®
5. Elbit Imaging Announces the Results of the Companys Unsecured Financial Creditors Meeting Approving the General Terms of Agreement to be Entered Into With Bank Hapoalim
6. Net Health Announces New Vice President of Training and Implementation
7. Celsion Corporation Announces Strategic Loan Facility
8. BioLineRx Announces New Positive Results in Phase 2a trial for Orally Available Inflammatory Bowel Disease Treatment
9. China Nepstar Chain Drugstore Announces Annual Dividend
10. Veracyte, Inc. Announces Third Quarter 2013 Financial Results
11. Orexigen Announces Successful Interim Analysis of Contrave Light Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... Calif. , Oct. 11, 2017  BioPharmX Corporation ... scientific team that developed an innovative way to use ... of the delivery of new drugs. ... Fall Clinical Dermatology Conference will show how researchers from ... Hospital, Harvard Medical School used a suite of imaging ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/10/2017)... Calif. , Oct. 10, 2017  NDS received FDA 510(k) ... — a medical-grade battery-powered display stand specifically designed for endoscopy environments. ... transform technology into a clinical solution to support the improvement of ... Innovative Design ... Mobile Wireless Solution ...
Breaking Medicine Technology:
(Date:10/13/2017)... Worth, TX (PRWEB) , ... October 13, 2017 ... ... financial planning agency serving communities in the greater Dallas, Miami, and Raleigh regions, ... young boy fighting to overcome a rare and deadly chromosome abnormality. , After ...
(Date:10/13/2017)... ... October 13, 2017 , ... While it’s often important ... problem. Fortunately, an inventor from Austin, Texas, has identified a solution. , She developed ... darkness or restricted lighting. As such, it eliminates the need to turn on a ...
(Date:10/13/2017)... ... 13, 2017 , ... PurhealthRX , a leading Health and Nutrition Company, ... Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market by ... be easily incorporated into liquid products, while reducing costs to end users. , The ...
(Date:10/13/2017)... ... ... Apple Rehab Shelton Lakes , which specializes in the delivery of ... part of a disaster drill on October 3rd. , Apple Rehab participated with the ... as well as the Connecticut Long Term Care Mutual Aid Plan (LTC-MAP). The ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
Breaking Medicine News(10 mins):